Managing DME When Anti-VEGF Response Is Limited - Top-Institutions - MDSpire

Managing DME When Anti-VEGF Response Is Limited

Retina Minute: Drs. Kuppermann and Singer discuss week-12 findings from the ERLYDEX trial in anti-VEGF suboptimal responders

  • By

  • Baruch D. Kuppermann, MD, PhD

  • Michael A. Singer, MD

  • March 1, 2026

  • 5 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    University of California, Irvine - Gavin Herbert Eye Institute
    University of California, Irvine - Gavin Herbert Eye Institute

    Irvine, CA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Diabetic Eye Disease

  • #2

    Massachusetts Eye and Ear Infirmary - Harvard Medical School
    Massachusetts Eye and Ear Infirmary - Harvard Medical School

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Diabetic Retinopathy

  • #3

    Bascom Palmer Eye Institute - University of Miami
    Bascom Palmer Eye Institute - University of Miami

    Miami, FL

    Key Differentiators

    • Ophthalmology
    • Retina
    • Diabetic Eye Disease

  • #4

    Wills Eye Hospital
    Wills Eye Hospital

    Philadelphia, PA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Diabetic Retinopathy

  • #5

    Johns Hopkins Wilmer Eye Institute
    Johns Hopkins Wilmer Eye Institute

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Retina
    • Diabetic Eye Disease

Original Source(s)

Managing DME When Anti-VEGF Response Is Limited

  • by Baruch D. Kuppermann, MD, PhD, Michael A. Singer, MD

  • March 1, 2026

Related Content

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Privosegtor Receives Breakthrough Drug Designation

In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.